NCT06800963View on ClinicalTrials.gov

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

February 29, 2028

Study Completion Date

February 29, 2028

Conditions
NMIBC
Interventions
BIOLOGICAL

Intravesical Recombinant Mycobacterium (rMBCG)

19.2e8 Colony-forming unit(s) CFU (1 vial) rMBCG via a urinary catheter in the bladder (ie, intravesical administration)

Trial Locations (2)

90720

Cancer & Blood Specialty Clinic, Los Alamitos

91203

OPN Healthcare, INC, Glendale

Sponsors

Lead Sponsor

ImmunityBio, Inc.
All Listed Sponsors
lead

ImmunityBio, Inc.

INDUSTRY